Literature DB >> 29072931

Effectiveness and Cost-Effectiveness of Tuina for Chronic Neck Pain: A Randomized Controlled Trial Comparing Tuina with a No-Intervention Waiting List.

Daniel Pach1, Mike Piper1, Fabian Lotz1, Thomas Reinhold1, Mirja Dombrowski1, Yinghui Chang2, Bin Liu2, Susanne Blödt1, Gabriele Rotter1, Katja Icke1, Claudia M Witt1,3,4.   

Abstract

OBJECTIVE: To evaluate whether tuina is more effective and cost-effective in reducing pain compared to no intervention in patients with chronic neck pain.
DESIGN: Single-center randomized two-armed controlled trial.
SETTING: University outpatient clinic specialized in Integrative Medicine.
SUBJECTS: Outpatients with chronic neck pain were randomly allocated to tuina or no intervention. INTERVENTION: Six tuina treatments within 3 weeks. OUTCOME MEASURES: The primary outcome was the mean neck pain intensity during the previous 7 days on a visual analogue scale after 4 weeks (VAS, 0-100 mm, 0 = no pain, 100 = worst imaginable pain). Secondary outcomes included Neck Pain and Disability Scale (NPDS), Neck Disability Index (NDI), health-related quality of life (12-item quality-of-life questionnaire [SF-12]), medication intake, and cost-effectiveness after 4 and 12 weeks. Statistical analysis included analysis of covariance adjusted for baseline values and a full economic analysis from a societal perspective.
RESULTS: Altogether, 92 outpatients were included (46 in both groups, 87% female, mean age 45.4 [standard deviation ±9.7], and mean VAS 57.7 ± 11.5). Tuina treatment led to a clinically meaningful reduction in neck pain intensity (group differences, 4 weeks: -22.8 mm [95% confidence interval, -31.7 to -13.8]; p < 0.001 and 12 weeks: -17.9 mm [-27.1 to -8.8], p < 0.001). No serious adverse events were observed. Total costs as well as quality-adjusted life years (QALYs) did not differ significantly between the groups. When taking group differences into account independently from their statistical significance, costs per QALY gained (incremental cost-effectiveness ratio) would range within a cost-effective area from €7,566 (for costs €10.28 per session) to €39,414 (cost €35 per session).
CONCLUSION: An additional treatment with six tuina sessions over 3 weeks was effective, safe and relatively cost-effective for patients with chronic neck pain. A future trial should compare tuina to other best care options.

Entities:  

Keywords:  Chinese Traditional Medicine; massage; medicine; neck pain; tuina

Mesh:

Year:  2017        PMID: 29072931     DOI: 10.1089/acm.2017.0209

Source DB:  PubMed          Journal:  J Altern Complement Med        ISSN: 1075-5535            Impact factor:   2.579


  4 in total

1.  Cost-Utility Analysis of Chuna Manual Therapy and Usual Care for Chronic Neck Pain: A Multicenter Pragmatic Randomized Controlled Trial.

Authors:  In-Hyuk Ha; Eun-San Kim; Sook-Hyun Lee; Yoon Jae Lee; Hyun Jin Song; Younhee Kim; Koh-Woon Kim; Jae-Heung Cho; Jun-Hwan Lee; Byung-Cheul Shin; Jinho Lee; Joon-Shik Shin
Journal:  Front Med (Lausanne)       Date:  2022-05-11

2.  The effect of osteopathic medicine on pain in musicians with nonspecific chronic neck pain: a randomized controlled trial.

Authors:  Gabriele Rotter; Isabel Fernholz; Sylvia Binting; Theresa Keller; Stephanie Roll; Benjamin Kass; Thomas Reinhold; Stefan N Willich; Alexander Schmidt; Benno Brinkhaus
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-12-10       Impact factor: 5.346

3.  App-Based Relaxation Exercises for Patients With Chronic Neck Pain: Pragmatic Randomized Trial.

Authors:  Daniel Pach; Susanne Blödt; Jiani Wang; Theresa Keller; Beatrice Bergmann; Alizé A Rogge; Jürgen Barth; Katja Icke; Stephanie Roll; Claudia M Witt
Journal:  JMIR Mhealth Uhealth       Date:  2022-01-07       Impact factor: 4.773

4.  Efficacy of Tuina in patients with chronic low back pain: study protocol for a randomized controlled trial.

Authors:  Shuaipan Zhang; Lingjun Kong; Qingguang Zhu; Zhiwei Wu; Jianhua Li; Min Fang; Wuquan Sun; Yanbin Cheng; Shanda Xu; Guangxin Guo; Xin Zhou; Zhizhen Lv
Journal:  Trials       Date:  2020-03-17       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.